Fatal cardiac arrest in two children: possible role of Ondansetron


Ondansetron ( Zofran ) is commonly used to treat vomiting in gastroenteritis, but has a United States FDA ( Food and Drug Administration ) black box warning for risk of Q wave to T wave time interval ( QT ) prolongation.

Two pediatric cases of fatal refractory cardiac arrest after administration of Ondansetron were reported.

A 10-year-old previously healthy boy presented to the emergency room with gastroenteritis symptoms. After intravenous fluids, morphine, antibiotics, and 2 doses of Ondansetron, the patient became unresponsive with agonal respirations and a wide complex tachycardia consistent with ventricular tachycardia.

In a second case, an 86-day-old infant with previously unidentified congenital cardiomyopathy presented to the Emergency department with gastroenteritis symptoms. The patient received Ondansetron and subsequently experienced repeated bouts of supraventricular tachycardia which progressed to ventricular fibrillation.

Resuscitation efforts failed in each case, and both patients expired.

Ondansetron can cause dose-dependent QT prolongation effects, which are more clinically relevant when other proarrhythmic elements are present.
There is very limited published experience on use of Ondansetron in children younger than 2 years.

These two cases join two previous case reports of death after Ondansetron administration for gastroenteritis.

In conclusion, patients may have hidden risk factors that, together with Ondansetron, could result in a proarrhythmic state that could lead to adverse effects, such as arrhythmias.
Administration of Ondansetron should be individualized and used cautiously in patients with risk factors for arrhythmia. ( Xagena )

Brenner SM, Boucher J, Pediatr Emerg Care 2016; 32: 779-784

XagenaMedicine_2016



Indietro

Altri articoli

COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying...


Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation often recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs...


Implantable cardioverter-defibrillator ( ICD ) use is associated with reduced short- and long-term mortality in patients with heart failure. Patients with...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Brukinsa ( Zanubrutinib ) capsules for...


The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...


In acute coronary syndrome ( ACS ), potassium imbalance at admission has been associated with in-hospital arrhythmias, cardiac arrest, and...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


As the Zika virus continues to spread globally, new evidence has emerged about the virus's potentially detrimental effects on the...


Sarcoidosis is an important diagnostic consideration in patients with ventricular tachycardia of unknown origin. The clinical course of ventricular tachycardia...